INTRODUCTION
Sixteen antiretroviral drugs have been approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection: seven nucleoside/nucleotide reverse transcription (RT) inhibitors (NRTI), six protease inhibitors (PIs), and three nonnucleoside RT inhibitors (NNRTI). In previously untreated individuals with drug-susceptible HIV-1 strains, combinations of three or more drugs from two drug classes can lead to prolonged virus suppression and immunologic reconstitution. However, the margin of success for achieving and maintaining virus suppression is narrow. Extraordinary patient effort is required to adhere to drug regimens that are expensive, inconvenient, and often associated with dose-limiting side effects. In addition to these hurdles, the development of drug resistance looms as both a cause and consequence of incomplete virus suppression that threatens the success of future treatment regimens.
RATIONALE FOR HIV-1 DRUG RESISTANCE TESTING
An increasing number of studies are showing that the presence of drug resistance before starting a new drug regimen is an independent predictor of virologic response to that regimen (reviewed in references 72, 75, 128, and 138) . In addition, several prospective controlled studies have shown that patients whose physicians have access to drug resistance data, particularly genotypic resistance data, respond better to therapy than control patients whose physicians do not have access to these assays (19, 47a, 50a, 92, Tables 1 and 2 ).
Genotypic testing is the most commonly used method of detecting resistant HIV-1 isolates and is one of the earliest applications of gene sequencing for clinical purposes. Although genotypic tests are more complex than typical antimicrobial susceptibility tests, their ability to detect mutations present as mixtures, even if the mutation is present at a level too low to affect drug susceptibility in a phenotypic assay, provides insight into the potential for resistance to emerge. They are also advantageous because they can detect transitional mutations that do not cause drug resistance by themselves but indicate the presence of selective drug pressure.
Genotypic testing has been shown to be clinically useful in four of five prospective randomized studies (19, 47a, 92, 380a ; Meynard, J. L., M. Vray, L. Monard-Joubert, S. . Several reviews on the genetic basis of HIV-1 drug resistance have recently been published (69, 127, 128, 235, 260, 337) . This review will focus on how knowledge of the genetic basis of HIV-1 drug resistance can be exploited to test for HIV drug resistance in clinical settings. HIV drug resistance is an interdisciplinary field; important data have been derived from structural biology, biochemistry, virology, and clinical studies. This review will integrate data from these different disciplines that are relevant to the development of new HIV drugs and to the optimal use of those HIV drugs that are already available.
EVOLUTION OF HIV-1 DRUG RESISTANCE
The evolution of HIV-1 drug resistance within an individual depends on the generation of genetic variation in the virus and on the selection of drug-resistant variants during therapy. HIV-1 genetic variability is a result of the inability of HIV-1 RT to proofread nucleotide sequences during replication (242) . It is exacerbated by the high rate of HIV-1 replication in vivo, the accumulation of proviral variants during the course of HIV-1 infection, and genetic recombination when viruses with different sequences infect the same cell. As a result, innumerable genetically distinct variants (quasispecies) evolve in individuals in the months following primary infection (50) .
The HIV-1 quasispecies within an individual undergo continuous genetic variation, competition, and selection. Development of drug resistance depends on the size and heterogeneity of the HIV-1 population within an individual, the extent to which virus replication continues during drug therapy, the ease of acquisition of a particular mutation (or set of mutations), and the effect of drug resistance mutations on drug susceptibility and virus fitness. Some mutations selected during drug therapy confer measurable phenotypic resistance by themselves, whereas other mutations increase resistance only when present with other mutations or compensate for the diminished replicative activity that can be associated with drug resistance. It has been estimated that every possible single point mutation occurs between 10 4 and 10 5 times per day in an untreated HIV-1-infected individual and that double mutants also occur commonly (50) . It is not known, however, whether multidrugresistant viruses already exist at low frequencies in untreated persons or if they are generated by residual viral replication during therapy (304) . Answers to this question depend on the effective population number of HIV-1 in vivo. Some authors have argued in favor of a high effective population number and a deterministic model of HIV-1 evolution in which chance effects play a small role (313) ; others have argued in favor of a lower effective population number and a stochastic model of HIV-1 evolution (31, 34, 107) .
Resistant virus strains can also be transmitted between individuals. In the United States and Europe, about 10% of new infections are with HIV-1 strains harboring resistance to at least one of three classes of anti-HIV drugs (16, 23, 30, 93, 144, 233, 234, 317, 357, 372, 384, 416 [61] [62] 1999) (Table 3) . 
IDENTIFYING AND CHARACTERIZING DRUG RESISTANCE MUTATIONS
HIV drug resistance is mediated by mutations in the molecular targets of drug therapy. Drug-resistant viruses are usually first identified by in vitro passage experiments in which viral isolates are cultured in the presence of increasing concentrations of an antiviral compound. Isolates identified in this manner are further characterized by sequencing to identify genetic changes arising during selective drug pressure and by in vitro susceptibility testing. In some cases, HIV-1 constructs containing specific mutations have been created using site-directed mutagenesis to directly assess the effect of specific mutations on drug susceptibility.
Drug susceptibility testing involves culturing a fixed inoculum of HIV-1 in the presence of serial dilutions of an inhibitory drug. The concentration of drug required to inhibit virus replication by 50% (IC 50 ) or 90% (IC 90 ) is the most commonly used measure of drug susceptibility. Drug susceptibility assays are not designed to determine the amount of drug required to inhibit virus replication in vivo, but rather to compare the drug concentration required to inhibit a fixed inoculum of the isolated virus with the concentration required to inhibit the same inoculum of wild-type virus.
Drug susceptibility results depend on multiple unstandardized factors including the inoculum of virus tested, the cells used for virus replication, and the means of assessing virus replication. Susceptibility testing of NRTIs is further complicated by the fact that NRTIs are triphosphorylated to their active form at different rates in different cell lines. The dynamic susceptibility range between wild-type and the most drug-resistant isolates depends on the drug tested and the susceptibility assay used. It is as low as 10-fold for some drugs and as high as 1,000-fold for others. The dynamic susceptibility range does not necessarily correlate with the potency of a drug; rather it provides a useful context for interpreting an individual susceptibility result. For example, a 10-fold reduction in susceptibility to a drug would be considered high-level resistance if the dynamic susceptibility range for that drug is 10-fold but not if it is 1,000-fold.
The process of identifying drug resistance mutations using virus passage studies and characterizing their impact by testing the susceptibility of site-directed mutants containing the same amino acid changes is highly rigorous but has several limitations. First, the spectrum of mutations developing during in vitro passage experiments is narrower than in isolates from treated patients. This is particularly true for patients receiving combinations of drugs targeting the same enzyme. Second, site-directed mutagenesis studies cannot capture the complicated patterns of mutations observed in clinical isolates and cannot account for the impact of background polymorphisms that may influence the viability and extent of resistance in isolates containing known drug resistance mutations. Finally, clinical data often provide additional insight into which mutations are the most significant in vivo.
To characterize the mutations responsible for drug resistance, it is therefore necessary to also study HIV-1 isolates from patients receiving treatment. Specifically, three additional types of data must be collected: correlations between mutations and drug susceptibility in clinical HIV isolates, correlations between mutations and the drug treatment histories of persons from whom the sequenced isolates have been obtained, and correlations between mutations and the virologic response to a new HIV drug regimen. HIV-1 isolates from persons failing drug therapy are crucial observations of HIV-1 evolution that show which mutations the virus uses to escape from drug suppression in vivo. Such data are particularly important for elucidating the genetic mechanisms of resistance to drugs that are difficult to test in vitro susceptibility tests. a Abbreviations: MDR, multidrug resistance, resistance within more than one class of drugs; NA, not available. In these studies, the following mutations were detected and considered genotypic evidence of resistance: for the NRTIs, M41L, D67N, T69D, K70R, L74V, M184V, L210W, and T215Y/F/S/D/C; for the NNRTIs, L100I, K101E, K103N, Y181C, and G190A; for the PIs, D30N, M46I/L/V, G48V, I54V, V82A, I84V, and L90M. In the study by Little et al., not all isolates had genotypic testing done, and the percent resistance represents a lower limit to the prevalence of genotypic resistance in that study.
b Grant et al., Antivir. Ther. 4(Suppl. Correlations between genotype and virologic response to a new regimen are essential for demonstrating the clinical significance of drug resistance mutations. Because drug resistance mutations arise in the enzymes targeted by therapy, many of these mutations compromise enzymatic function. Although, the fitness of these variants can be tested in vitro, such fitness tests are not standardized and are unable to detect subtle changes in replication or the likelihood that certain defects in fitness may be readily compensated for by other genetic changes in the virus while other defects may be more crippling. How a mutant virus responds to a new drug regimen in vivo, therefore provides the most meaningful test of virus fitness.
Because insertions and deletions are uncommon in HIV-1 RT and protease, researchers have been able to develop a standardized numbering system for HIV-1 drug resistance mutations. The most commonly used wild type reference sequence is the subtype B consensus sequence. This sequence was originally derived from alignments in the HIV Sequence Database at Los Alamos (205) and can now be found on the HIV RT and Protease Sequence Database (339) . The standardized numbering system and reference sequence have led to the development of a shorthand for mutations in which a letter indicating the consensus B wild-type amino acid is followed by the amino acid residue number, followed by a letter indicating the mutation (e.g., T215Y).
So many mutations in both the protease and RT have been associated with drug resistance that it has become customary to label some mutations either primary (or less commonly major) and other mutations secondary (or minor). The term primary is used to indicate mutations that reduce drug susceptibility by themselves whereas the term secondary is used to indicate mutations that reduce drug susceptibility or improve the replicative fitness of isolates with a primary mutation. However, the labels primary and secondary are not strictly defined. For example, some mutations might be considered to be primary for one drug but secondary for another drug. Moreover, secondary mutations commonly arise before primary mutations.
PI RESISTANCE

HIV-1 Protease
The HIV-1 protease enzyme is responsible for the posttranslational processing of the viral gag-and gag-pol-encoded polyproteins to yield the structural proteins and enzymes of the virus. The enzyme is an aspartic protease composed of two noncovalently associated, structurally identical monomers 99 amino acids in length (Fig. 1) . Its active site resembles that of other aspartic proteases and contains the conserved triad, AspThr-Gly, at positions 25 to 27. The hydrophobic substrate cleft recognizes and cleaves 9 different peptide sequences to produce the matrix, capsid, nucleocapsid, and p6 proteins from the gag polyprotein and the protease, RT, and integrase proteins from the gag-pol polyprotein. The enzyme contains a flexible flap region that closes down on the active site upon substrate binding.
Resistance is mediated by at least two different types of mechanisms. Mutations in the substrate cleft cause resistance by reducing the binding affinity between the inhibitor and the mutant protease enzyme. Other mutations either compensate for the decreased kinetics of enzymes with active site mutations or cause resistance by altering enzyme catalysis, dimer stability, inhibitor binding kinetics, or active site reshaping through long-range structural perturbations (97) . The three-dimensional structures of wild-type HIV-1 protease and several drugresistant mutant forms bound to various inhibitors have been determined by crystallography (1, 2, 15, 47, 238, 239) .
PI resistance usually develops gradually from the accumulation of multiple primary and secondary mutations. Most primary mutations, by themselves, cause a two-to fivefold reduc- The protease inhibitor resistance mutations are shown for the subunit on the left but not for the subunit on the right. The protease was cocrystallized with indinavir, which is displayed in space-fill mode. This drawing is based on a structure published by Chen et al. (46) . tion in susceptibility to one or more PIs. However, this level of resistance is often insufficient to interfere with the antiviral activity of these drugs. Higher levels of resistance are resulting from the accumulation of additional primary and secondary mutations are often required for clinically significant reductions in drug susceptibility. This requirement for multiple mutations to overcome the activity of PI inhibitors has been referred to as a "genetic barrier" to drug resistance (54, 188, 265) .
Sequence analyses of drug resistant isolates has shown that mutations at several of the protease cleavage sites are also selected during treatment with protease inhibitors (60, 87, 180, 187, 237, 240, 420) . Growth kinetic studies have shown that cleavage site mutations in some circumstances improve the kinetics of protease enzymes containing drug resistance mutations and that the cleavage site mutations are compensatory rather than primary. Moreover, there have been no reports that changes at cleavage sites alone can cause PI resistance.
PIs
There are six FDA-approved PIs: amprenavir, indinavir, lopinavir (manufactured in combination with ritonavir), nelfinavir, ritonavir, and saquinavir. The spectrum of mutations developing during therapy with indinavir, nelfinavir, saquinavir, and ritonavir have been well characterized (9, 24, 54, 61, 265, 281, 320, 334) , but fewer data are available for amprenavir (237a) and lopinavir (35). The dynamic susceptibility range for indinavir, ritonavir, saquinavir, nelfinavir, and lopinavir is about 100-fold in most drug susceptibility assays (148, 149, 290, 393 ; Brun, S., D. Kempf, J. Isaacson, A. Molla, H. Mo, C. Benson, and E. Sun, abstract 452, 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., 2001). The dynamic susceptibility range for amprenavir is about 10-to 20-fold. In patients receiving PI combinations or in patients maintaining high PI levels, virologic rebound requires multiple mutations and high-levels of phenotypic resistance.
Pharmacologic factors influence the clinical efficacy of PIs more than that of the other two classes of HIV drugs. Virologic response is highly correlated with the ratio of the trough drug concentration divided by the inhibitory concentration of the drug (e.g., the IC 50 in a standardized assay), a ratio that is commonly referred to as the inhibitory quotient (IQ) (153) . Drug levels achieved during PI monotherapy can vary greatly among individuals, often resulting in low IQs. This has led to the practice of administering subtherapeutic doses of ritonavir (a P450 enzyme inhibitor) in combination with other PIs to increase their drug levels-a practice known as PI boosting. Lopinavir is formulated in a fixed combination with ritonavir; and saquinavir, indinavir, and amprenavir are also increasingly likely to be administered with low-dose ritonavir (162). Boosted PIs require higher levels of resistance than PIs given as monotherapy before significant loss of antiviral activity and virologic rebound occur.
Protease Substrate Cleft Mutations
V82A/T/F/S mutations occur predominantly in HIV-1 isolates from patients receiving treatment with indinavir and ritonavir (54, 265) . V82A also occurs in isolates from patients receiving prolonged therapy with saquinavir following the development of the mutation G48V (330, 409 [70] [71] 2000) resistance to each PI. I84V tends to develop in isolates that already have the mutation L90M and is rarely the first major mutation to develop in patients receiving a PI (178).
G48V occurs primarily in patients receiving saquinavir and rarely in patients receiving indinavir. This mutation causes 10-fold resistance to saquinavir and about 3-fold resistance to indinavir, ritonavir, and nelfinavir (149, 172, 282, 409) . Isolates with a combination of mutations at codons 48, 54 , and 82 have been tested against each of the PIs except lopinavir and found to have high-level resistance to each (277, 343) . D30N occurs solely in patients receiving nelfinavir and confers no in vitro or clinical cross-resistance to the other PIs (243, 282, 409) . Cross-resistance to indinavir, ritonavir, and saquinavir has been observed in isolates that have D30N along with mutations at positions 88 and 90 (279) .
I50V has been reported only in patients receiving amprenavir as their first PI (237a). In addition to causing reduced amprenavir susceptibility, it has been shown to increased k i values to ritonavir, indinavir, and nelfinavir in biochemical studies (Xu, R., W. 43, 2001 ) and to cause in vitro cross-resistance to ritonavir and lopinavir (279, 280, 378) . Possibly because of the rarity of this mutation, there have been few reports of multidrug-resistant isolates containing this mutation.
V32I occurs in patients receiving indinavir, ritonavir, and amprenavir. It usually occurs only in association with other PI resistance mutations in the substrate cleft or flap and by itself appears to cause minimal resistance to any one drug. R8K and R8Q are substrate cleft mutation that cause high-level resistance to one of the precursors of ritonavir (A-77003) (124, 152) , but they have not been reported with the current PIs.
Protease Flap Mutations
The protease flap region (positions 45 to 56) extends over the substrate-binding cleft and must be flexible to allow entry and exit 252 SHAFER CLIN. MICROBIOL. REV.
of the polypeptide substrates and products (346) . In addition to G48V and I50V, which are also in the substrate cleft, mutations at positions 46, 47, 53, and 54 make important contributions to drug resistance. Mutations at position 54 (generally I54V, less commonly I54T/L/M) contribute resistance to each of the six approved PIs and have been commonly reported during therapy with indinavir, ritonavir, amprenavir and saquinavir, and lopinavir (55, 237a, 265, 281, 320) . I54L and I54 M are particularly common in persons receiving amprenavir and have been shown to have a greater effect on amprenavir than the mutation I54V (237a).
Mutations at position 46 contribute to resistance to each of the PIs except saquinavir and have been commonly reported during therapy with indinavir, ritonavir, amprenavir, and nelfinavir (55, 237a, 265, 281, 320) . Mutations at codon 47 have been reported in patients receiving amprenavir, indinavir, and ritonavir, and often occur in conjunction with the nearby substrate cleft mutation, V32I. F53L has been reported rarely in patients receiving PI monotherapy, but it occurs in more than 10% of patients treated with multiple PIs (178). It has most recently come to attention as one of the mutations associated with phenotypic resistance to lopinavir in multivariate analyses (188).
Protease Mutations at Other Conserved Residues
L90M has been reported in isolates from patients treated with saquinavir, nelfinavir, indinavir, and ritonavir. (238, 239, 274) but the mechanism by which L90M causes PI resistance is not known.
Mutations at codon 73, particularly G73S, have been reported in 10% of patients receiving indinavir and saquinavir monotherapy and occasionally during nelfinavir monotherapy (178, 334). However, this mutation occurs most commonly in patients failing multiple PIs, usually in conjunction with L90M. Mutations at position 88 (N88D and N88S) commonly occur in patients receiving nelfinavir and occasionally in patients receiving indinavir. By itself, a mutation at this position causes lowlevel nelfinavir resistance. However, a mutation at this position causes high-level nelfinavir resistance in the presence of D30N or M46I (290, 421) . N88S (but not N88D) has been shown to hypersensitize isolates to amprenavir (421) , but the clinical significance of this finding is not known. L24I has been reported only in HIV-1 isolates from patients receiving indinavir (55) and has not been shown to confer cross-resistance to other PIs, except possibly lopinavir (188).
Polymorphic Sites Contributing to Resistance
Amino acid variants at seven polymorphic positions, including codons 10, 20, 36, 63, 71, 77, and 93, also make frequent contributions to drug resistance. These mutations do not cause drug resistance by themselves. Some contribute to drug resistance when present together with other protease mutations; whereas others compensate for the decrease in catalytic efficiency caused by other mutations (56, 241, 246, 272, 310) .
Mutations at codons 10, 20, 36, and 71 occur in up to 5 to 10% of untreated persons infected with subtype B viruses. However, in heavily treated patients harboring isolates with multiple mutations in the substrate cleft, flap, or at codon 90, the prevalence of mutations at these positions increases dramatically. Mutations at codon 10 and 71 increase to 60 to 80%, whereas mutations at codons 20 and 36 increase to 30 to 40% (148, 177) . Codon 63 is the most polymorphic protease position. In untreated persons about 45% of isolates have 63L (considered the subtype B consensus), about 45% have 63P, and about 10% have other residues at this position. However, the prevalence of amino acids other than L increases to 90% in heavily treated patients (177, 413). Mutations at codons 77 and 93 double in prevalence from 15 to 20% in untreated persons to 30 to 40% in heavily treated persons (177).
In some HIV-1 subtypes, mutations at codons 10, 20, and 36 occur at higher rates than they do in subtype B isolates (58, 114, 293, 331) . It has been hypothesized that individuals harboring isolates containing multiple accessory mutations may be at a greater risk of virologic failure during PI therapy (288, 289) . However, most studies to date have not supported this hypothesis (3a, 25, 106, 208, 288, 289, 329) .
PI Cross-Resistance Patterns
Most PI resistance mutations confer resistance to multiple PIs and should be considered class-specific rather than drug-specific mutations. In a study of over 6,000 HIV-1 isolates tested for susceptibility to indinavir, nelfinavir, ritonavir, and saquinavir, 59% to 80% of isolates with a 10-fold decrease in susceptibility to one PI also had a 10-fold decrease in susceptibility to at least one other PI (148) . In another study of 3000 HIV-1 isolates, susceptibility to indinavir, ritonavir, and lopinavir were highly correlated (279) . Isolates that were resistant to these drugs were generally also resistant to nelfinavir; however, isolates resistant to nelfinavir due to D30N were generally not cross-resistant to other drugs. Susceptibilities to saquinavir and amprenavir were less well correlated to one another or to the other PIs (279) . Similar crossresistance patterns among the PIs have been reported in other smaller studies (185, 300, 321, 322) .
Patients in whom nelfinavir-resistant isolates arise after nelfinavir treatment often respond to a regimen containing a different PI because D30N and N88D/S confer little crossresistance to other PIs (185, 423). But because as many as 15% of nelfinavir failures may be associated with mutations at codons 46 and/or 90, virologic failure while receiving nelfinavir does not guarantee susceptibility to other PIs (9, 281) . Nelfinavir is usually unsuccessful as salvage therapy because most of the mutations that confer resistance to other PIs confer crossresistance to nelfinavir (148, 227, 399) .
In vitro drug susceptibility studies suggest that patients failing other PIs often have isolates that retain susceptibility to amprenavir and saquinavir (300, 321) . But neither drug has demonstrated usefulness when administered as salvage therapy without ritonavir boosting (82, 92a, 102) . In a study of ritonavir/saquinavir salvage therapy, the number of mutations at positions 46, 48, 54, 82, 84, and 90 predicted the virologic response at 4, 12, and 24 weeks. Patients with three or more of these mutations had no response to [70] [71] 2000) . A decreased response to therapy was observed only in those patients that had Ն6 of the listed mutations. Subsequent analyses have suggested that mutations at positions 10, 20, 46, 54, and 82 may be more predictive than the others listed (40, 264) and that other mutations, including I50V and G73S may contribute to resistance in different patient cohorts (135, 279) . Nonetheless, the large number of mutations required to interfere with a clinical response to therapy demonstrates the high genetic barrier to resistance associated with a drug that achieves high levels in vivo.
In summary, clinical studies have shown that most patients developing virologic failure during treatment with one PI have a diminished virologic response to treatment with a second PI ( Table . There continues to be great interest in discovering ways to use genotypic data to help switch from one PI to another, although the second PI is increasingly being given as part of a boosted regimen.
Investigational PIs
The most advanced of the new PI are BMS-232,632 and tipranavir. BMS-232,632 is a highly potent inhibitor of HIV-1 protease with a favorable pharmacokinetic profile that allows once daily dosing. In phase I/II studies it has demonstrated anti-HIV activity similar to that of each of the approved PIs (308; Squires, K., J. Gatell, P. Piliero, I. Sanne, R. Wood, and S. M. Schnittman, abstract 15 . The drug's potency and pharmacokinetic profile make it a promising candidate for approval. But because its resistance profile overlaps with that of the other approved PIs its usefulness as a salvage therapy is uncertain.
Tipranavir is a nonpeptidomimetic PI with greater flexibility in conforming to enzyme variants with PI resistance mutations (219, 260, 383) . However, tipranavir is less potent than other PIs both in vitro and in vivo, and has a narrower dynamic susceptibility range compared with other PIs (14, 219, 316) . The narrow dynamic susceptibility range makes it difficult to assess the clinical significance of the decreased cross-resistance between tipranavir and the currently approved PIs. Data are pending on its activity when used in combination with ritonavir.
NRTI RESISTANCE
HIV-1 RT
The RT enzyme is responsible for RNA-dependent DNA polymerization and DNA-dependent DNA polymerization. RT is a heterodimer consisting of p66 and p51 subunits. The p51 subunit is composed of the first 440 amino acids of the RT gene. The p66 subunit is composed of all 560 amino acids of the RT gene. Although the p51 and p66 subunits share 440 amino acids, their relative arrangements are significantly different. The p66 subunit contains the DNA-binding groove and the active site; the p51 subunit displays no enzymatic activity and functions as a scaffold for the enzymatically active p66 subunit. The p66 subunit has five subdomains, including the fingers, palm, and thumb subdomains that participate in polymerization, and the connection and RNase H subdomains.
Most RT inhibitor resistance mutations are in the 5Ј polymerase coding regions, particularly in the "fingers" and "palm" subdomains ( Fig. 2) . Structural information for RT is available from X-ray crystallographic studies of RT bound to an NNRTI (198) , unliganded RT (309), and RT bound to double-stranded DNA (158, 171) . However, only one structure exists that enables visualization of the interaction between the catalytic complex and the incoming deoxynucleoside triphosphate (dNTP) (158) . There have been fewer structural determinations of mutant RT enzymes than of mutant protease enzymes (302, 318) .
NRTIs
Six nucleoside analogs and one nucleotide analog have been approved by the Food and Drug Administration (FDA). The nucleoside analogs include zidovudine, didanosine, zalcitibine, stavudine, lamivudine, and abacavir. Abacavir, which was approved in 1998 is the most recently approved nucleoside. Tenofovir, which was approved in late 2001, is the only FDAapproved nucleotide analog. Both nucleoside and nucleotide analogs are prodrugs that must be phosphorylated by host cellular enzymes. Nucleosides must be tri-phosphorylated; nucleotides, because they already have one phosphate moiety, must be di-phosphorylated. Phosphorylated NRTIs compete with natural dNTPs for incorporation into the newly synthesized DNA chains where they cause chain termination. Because both nucleoside and nucleotide analog RT inhibitors act by a similar mechanism, the abbreviation NRTIs will be used for both classes of compounds.
There are two biochemical mechanisms of NRTI drug resistance. The first mechanism is mediated by mutations that allow the RT enzyme to discriminate against NRTIs during synthesis, thereby preventing their addition to the growing DNA chain (158, 226, 319) . The second mechanism is mediated by nucleotide excision mutations (NEMs) that increase the rate of hydrolytic removal of the chain-terminating NRTI and enable continued DNA synthesis (6, 7, 252, 254) .
In most drug susceptibility assays, the dynamic susceptibility range is Ͼ100-fold for zidovudine and lamivudine and 15-to 20-fold for didanosine, stavudine, zalcitibine, abacavir, and tenofovir (393) . Mutant isolates from patients failing therapy with zidovudine, lamivudine, and abacavir usually have measurable phenotypic drug resistance. In contrast, mutant isolates from patients failing therapy with stavudine or didanosine are often found to be drug susceptible in phenotypic assays. Because tenofovir has only recently been approved, there are fewer data on the genotypic correlates of drug resistance and on how well these changes can be detected in phenotypic assays. The difficulty in detecting didanosine resistance is thought to be an artifact of susceptibility testing caused by the inefficient conversion of didanosine to the active compound ddATP when stimulated lymphocytes are used for susceptibility testing (111) . The difficulty in detecting stavudine resistance may also be an artifact of the current susceptibility tests that rely on stimulated lymphocytes (230, 253) .
NEMs
The most common mutations occurring in clinical HIV-1 samples obtained from patients receiving NRTIs were originally identified for their role in causing zidovudine resistance. Various combinations of these mutations which occur at codons 41, 67, 70, 210, 215, and 219 (133, 156, 182, 222) , have been shown to mediate both ATP and pyrophosphate (PP)-dependent hydrolytic removal of zidovudine and stavudine monophosphate from a terminated cDNA chain (6, 252, 254) and cause a compensatory increase in RT processivity (6, 8, 39) . ATP-dependent hydrolytic removal of ddNTP, which traps the unblocked ddNTP in an inactive dinucleoside polyphosphate moiety, is more clinically significant than pyrophosphatedependent hydrolytic removal, which merely regenerates an active ddNTP (262) .
In a ddNTP-terminated primer, the presence of the dNTP that would have been incorporated next, had the primer been free for elongation, results in the formation of a stable "deadend" catalytic complex between RT, primer, template, and dNTP (29, 230, 262, 379) . The formation of such a dead-end complex may interfere with the ability of NEMs to facilitate the resumption of virus DNA chain elongation. Biochemical and structural modeling studies have suggested that the bulky azido group of zidovudine may interfere with the formation of a dead-end catalytic complex by sterically preventing the addition of the next dNTP (29, 230) . This observation may explain, at least in part, why the NEMs cause the highest levels of phenotypic resistance to zidovudine, despite the fact that biochemical studies have shown that some combinations of NEMs elevate ATP-dependent removal of blocked stavudine-monophosphate (MP) to the same degree as zidovudine-MP (230, 253) .
The structural basis underlying the NEMs mechanism of During the past few years, several studies have shown that the NEMs are associated with resistance not just to zidovudine, but also to stavudine, abacavir, and to a lesser extent, to didanosine, zalcitibine, and tenofovir (259, 262, 398) . The NEMs are selected primarily in patients treated with zidovudine or stavudine alone or in combination with other NRTIs (27, 49, 169, 203, 232, 266, 285, 291, 305, 311, 335, 353 (261) . There are few data on the development of NEMs in patients receiving zalcitibine or tenofovir without other NRTIs.
K70R causes low-level (four-to eightfold) zidovudine resistance and is usually the first drug resistance mutation to develop in patients receiving zidovudine monotherapy (27, 64) . T215Y/F results from a two base-pair mutation and causes intermediate (10-to 20-fold) zidovudine resistance. It arises in patients receiving dual NRTI therapy, as well as, in those receiving zidovudine monotherapy (207, 224, 335) . T215S/C/D are transitional mutations between wild-type and Y or F that do not cause reduced drug susceptibility but rather indicate the presence of previous selective drug pressure (67, 221, 417) . Mutations at positions 70 and 215 are antagonistic in their effect on zidovudine resistance and these two mutations rarely occur together unless additional NEMs are also present (27) .
Mutations at positions 41 and 210 usually occur with mutations at position 215 (133, 156, 414) . Mutations at positions 67 and 219 may occur with mutations at position 70 or with mutations at position 215. T215Y and K219Q are associated with increased processivity. L210W is strongly associated with M41L and T215F/Y and decreases the susceptibilities of isolates with these mutations by several fold. L210W may stabilize the interaction of 215YF with the dNTP binding pocket (262, 414) . In patients failing multiple dual nucleoside therapy it is not unusual for isolates to have four, five, or even all six NEMs.
Clinical studies have shown that the NEMs, particularly mutations at position 215 interfere with the clinical response to zidovudine (203, 303) , stavudine (353) , abacavir (102, 191, 214) , didanosine (155, 173) , and most dual NRTI combinations . The extent to which NEMs interfere with response to tenofovir is not known; however, preliminary data presented to the FDA have shown that tenofovir usually retains antiviral activity even in patients with extensive previous NRTI therapy.
The NEMs reduce zidovudine susceptibility more than any other drug. Both K70R and T215Y cause reproducible reductions in drug susceptibility regardless of the susceptibility assay used. Phenotypic resistance to other NRTIs generally requires multiple NEMs. The presence of four or more NEMs will typically cause Ͼ100-fold decreased susceptibility to zidovudine, five-to sevenfold decreased susceptibility to abacavir, but usually not more than two-to threefold decreased susceptibility to stavudine, didanosine, zalcitibine, and tenofovir (134, 217, 230, 250, 259, 262, 354, 398) .
The NEMs cause minimal lamivudine resistance and do not greatly compromise lamivudine activity (3) except to the extent that they interfere with the synergism between lamivudine and zidovudine and lamivudine and stavudine. One abstract that correlated the presence of NEMs with low-level lamivudine resistance (Skowron, G., J. Whitcomb, M. Wesley, C. Petropoulos, N. Hellmann, M. Holodniy, J. Kolberg, J. Detmer, M. T. Wrin, and K. Frost, abstract 81, Antivir. Ther. 4[Suppl. 1]:55, 1999) relied on a point mutation assay and did not account for other RT mutations which were likely to have explained the results (e.g., codons 44 and 118 [147] ).
M184V
M184V causes high-level (Ͼ100-fold) lamivudine resistance and emerges rapidly in patients receiving lamivudine monotherapy (26, 326, 377) . This mutation is also usually the first to develop in isolates from patients receiving incompletely suppressive lamivudine-containing regimens (81, 142, 236, 266a). M184V is also selected during therapy with abacavir (134, 261, 376) and less commonly during therapy with zalcitibine and didanosine (122, 351, 410) . M184V causes about 2-fold resistance to these drugs (122, 263, 290, 376, 410) .
M184I results from a G to A mutation (ATG to ATA) and usually develops before M184V in patients receiving lamivudine because HIV-1 RT is more prone to G to A mutations than to A to G mutations (ATG to GTA) (174, 189) . Although M184I also causes high-level resistance to lamivudine, the enzymatic efficiency of M184I is less than that of M184V and nearly all patients with mutations at this position eventually also develop M184V (107) .
M184V alone renders lamivudine ineffective but may not significantly compromise virologic response to treatment with abacavir (145, 179, 391, 399a) . However, M184V in combination with multiple zidovudine resistance or in combination with mutations at positions 65, 74, or 115 leads to both in vitro and in vivo abacavir resistance (134, 179, 277, 343 ; Lanier, R., J. Scott, H. Steel, B. Hetherington, M. Ait-Khaled, G. Pearce, W. Spreen, and S. Lafon, abstract 82, Antivir. Ther. 4[Suppl. 1]: 56, 1999) . The effect of M184V on the virologic response to didanosine-containing regimens has been less well studied though in one small observational study showed that in heavily treated patients infected with isolates containing multiple NEMs and M184V, a change from lamivudine to didanosine VOL. 15, 2002 GENOTYPIC TESTING FOR HIV-1 DRUG RESISTANCE 257 was usually associated with an RNA decrease of Ն0.5 log 10 RNA (315) . Position 184 is in a conserved part of the RT close to the active site. M184V sterically hinders certain NRTIs, particularly lamivudine, while still allowing the enzyme to function (318) . The possibility that isolates containing M184V are compromised was suggested by the initial lamivudine monotherapy studies which showed that RNA levels remained about 0.5 log copies below their starting value in patients receiving lamivudine for 6 to 12 months despite the presence of lamivudineresistant isolates containing M184V (98, 167, 296) . Several studies have shown that in vitro RT enzymes with M184V displayed increased fidelity (89, 275, 396) and others decreased processivity (12, 13, 28, 348) . The clinical significance of these biochemical studies is not known and the increased fidelity does not appear to limit the ability of HIV to develop new mutations under continued selective drug pressure (176, 190) .
M184V reverses T215Y-mediated zidovudine resistance (26, 223, 377) ; in plaque-forming assays, HIV-1 isolates containing M41L/T215Y displayed 64-fold resistance, while isolates containing M41L/T215Y and M184V were just 4-fold resistant. Resensitization may be due to the ability of M184V to impair the rescue of chain-terminated DNA synthesis (115) and does not appear to apply to zidovudine resistance caused by Q151M (342) . This resensitization is probably clinically significant and explains the slow evolution of phenotypic zidovudine resistance in patients receiving zidovudine plus lamivudine (209, 223, 247) . Resensitization, however, can be overcome by the presence of four or more zidovudine resistance mutations (343, 377) . M184V also appears to reverse the effect of the classical zidovudine mutations on resistance to stavudine and tenofovir, but not abacavir (89, 257, 270, 277) .
Mutations at Codons 65, 69, 74, and 75
Positions 64 to 72 form a loop between the ␤2 and ␤3 strands in the fingers region of the RT, which makes important contacts with the incoming dNTP during polymerization (158, 319) . In addition to the zidovudine-resistance mutations at codons 67 and 70, this region contains several other NRTIresistance mutations. The most common mutations in this region occur at position 69 and include T69D/N/S/A, as well as single and double amino acid insertions.
T69D was initially identified as causing resistance to zalcitibine (104) but substitutions at this position have since been reported after treatment with each of the available NRTIs. In site-directed mutagenesis studies, other mutations at this position including T69N, T69S, and T69A have been shown to confer resistance to zidovudine, didanosine, zalcitibine, and stavudine (404a) . It also appears likely that mutations at position 69 may contribute to resistance to each of the NRTIs when they occur together with NEMs (149, 257, 397, 404a) .
Insertions at position 69 occur in about 2% of heavily treated HIV-1-infected patients (390) . By themselves, these insertions cause low-level resistance to each of the NRTIs, but isolates containing insertions together with T215Y/F and other zidovudine-resistance mutations have high-level resistance to each of the NRTIs (63, 218, 248, 373, 406) . Insertions at this position are associated with about 20-fold resistance to tenofovir, which is the highest reported level of resistance to this drug (258). The precise mechanism by which this mutation causes resistance is not known with certainty but one paper suggests that higher levels of resistance occur in the presence of ATP suggesting that this mutation may act in a manner similar to the NEMs by causing ATP-mediated primer unblocking (230) . Single amino acid deletions between codons 67 to 70 occur in Ͻ1% of heavily treated patients (164 to 166, 405). These deletions contributes to resistance to each of the NRTIs in patients with viruses containing multiple NRTI mutations. L74V occurs commonly during didanosine and abacavir monotherapy (202, 261, 338, 410) and confers two-to fivefold resistance to didanosine and zalcitibine (368, 410) and two-to threefold resistance to abacavir (376) . L74V is sufficient to cause virologic failure in patients receiving didanosine monotherapy (202) but additional mutations may be required to cause virologic failure to abacavir monotherapy. L74V causes hypersensitivity to zidovudine and possibly also to stavudine (368) and is consequently rarely observed in patients receiving dual nucleoside therapy with didanosine/zidovudine or didanosine/stavudine (49, 200, 285, 335, 338) . L74V has also been shown to be cause decreased RT processivity in enzymatic studies and decreased replication in cell culture (347, 348) .
K65R confers intermediate levels of resistance to didanosine, abacavir, zalcitibine, lamivudine, and tenofovir (120, 121, 259, 261, 290, 359, 367, 376, 397, 419) . This mutation has been shown to increase the replication fidelity of HIV-1 RT in vitro and to cause increased enzymatic processivity mediated by a decrease in the rate of template-primer dissociation (5, 344) . K65R occurs rarely in vivo (404, 413) , and the biological and clinical significance of these biochemical findings are not known.
V75T develops in isolates cultured in the presence of increasing concentrations of stavudine and causes about fivefold resistance to stavudine, didanosine, and zalcitibine (212) . Biochemical data and modeling data suggest that mutations at this position cause drug resistance through nucleotide discrimination and possibly also through a non-ATP-mediated mechanism of primer unblocking (230, 327) . V75T occurs rarely even in patients receiving stavudine. V75I generally occurs in isolates that also have the multinucleoside resistance mutation, Q151M. The phenotypic effects of other mutations at this position including V75 M/A have not been well-characterized.
Multinucleoside Resistance Due to Q151M
Q151M is a 2-bp change in a conserved RT region that is close to the first nucleotide of the single-stranded nucleotide template (158, 350) . This mutation develops in up to 5% of patients who receive dual NRTI therapy with didanosine in combination with zidovudine or stavudine (49, 181, 285, 323, 335, 338, 390) . Q151M alone causes intermediate levels of resistance to zidovudine, didanosine, zalcitibine, stavudine, and abacavir (168, 342, 350, 389) . Q151M is generally followed by mutations at positions 62, 75, 77, and 116. Isolates with V75I, F77L, F116Y, and Q151M have high-level resistance to each of these NRTIs, low-level resistance to lamivudine and tenofovir (259, 277) . HIV-1 isolates with Q151M usually contain few, if any, NEMs.
Other NRTI Resistance Mutations
E44DA and V118I each occur in about 1% of untreated individuals (177). The prevalence of these two mutations is much higher in isolates obtained from patients receiving dual NRTI combinations, particularly in isolates containing multiple zidovudine resistance mutations (74, 177). When present in combination, E44D and V118I cause intermediate lamivudine resistance (147) . However, the frequent occurrence of these mutations even in patients who have not received lamivudine suggests a much broader role.
G333E is a polymorphism that has been reported in 4 of 70 (6%) untreated persons and 26 of 212 (12%) of persons receiving NRTIs (109) . G333E has been reported to facilitate zidovudine resistance in isolates from patients receiving zidovudine and lamivudine who also have multiple NEMs (184). However, dual resistance to these drugs usually emerges without this change (247, 343) . There are no data suggesting that this mutation by itself reduces zidovudine susceptibility. Two abstracts have suggested that in some isolates the common polymorphisms R211K and L214F also facilitate dual zidovudine and lamivudine resistance in the presence of mutations at positions 41, 184, and 215 (262, 380) . P157A/S is a rare mutation associated with lamivudine resistance. This mutation was first identified in a feline immunodeficiency virus isolate cultured in the presence of lamivudine and has subsequently shown to be associated with high-level lamivudine resistance even in isolates lacking M184V (291, 362, 363) .
NRTI Cross-Resistance Patterns
The NEMs confer some degree of clinically significant resistance to all NRTIs except lamivudine. The lamivudine resistance mutation, M184V, confers some degree of cross-resistance to all NRTIs except zidovudine, stavudine, and tenofovir. Indeed, M184V and several other NRTI-resistance mutations including L74V and possibly K65R (226) interfere with the effect of the NEMs. The mutational antagonism between the NEMs and several of the mutations that act by allowing RT to discriminate against NRTIs probably explains the clinical synergism observed with certain dual NRTI combinations such as zidovudine/lamivudine, stavudine/lamivudine, zidovudine/didanosine, and stavudine/didanosine.
High-level resistance to both drugs in a dual NRTI combination usually requires multiple NRTI resistance mutations. Two genetic mechanisms of multidrug resistance have received much attention: (i) Q151M usually together with V75I, F77L, and F116Y; and (ii) a double amino acid insertion at position 69 in combination with T215Y/F and other NEMs. These two mutational patterns, however, are responsible for only a minority of multidrug resistant isolates. Multidrug resistance more commonly results from a combination of Ն4 NEMs, M184V, and 1 to 2 mutations in the ␤2-␤3 loop, particularly at position 69.
The extent of cross-resistance between one dual NRTI combination and a second dual NRTI combination is currently being evaluated in clinical trials (360) . Preliminary data suggest that patients switching from one dual NRTI combination to a second dual NRTI combination will generally have some response as long as high-level resistance to the first combination VOL. 15, 2002 GENOTYPIC TESTING FOR HIV-1 DRUG RESISTANCE 259
has not yet emerged. Because of the high-level of cross-resistance between zidovudine and stavudine, it is unlikely that substituting one drug for the other is likely to be highly effective. There appears to be less clinical cross-resistance between lamivudine and didanosine and a salvage regimen that substitutes one of these drugs for the other is likely to have some activity. The optimal uses of abacavir and tenofovir, the two most recently approved NRTIs have not yet been defined. In previously untreated patients, abacavir is highly potent, reducing plasma HIV-1 RNA levels by Ն1.5 log 10 copies/ml. Its activity in treated patients, however, is compromised by the fact that a combination of M184V together with Ն3 NEMs appear to prevent a clinical response to the addition of this drug (214). This would suggest that its main role should be as part of an initial treatment regimen and not for salvage therapy. Preliminary data presented to the FDA from phase III trials in which tenofovir was added to a failing treatment regimen suggest that this drug may be uniquely effective (reducing plasma HIV-1 RNA levels by Ն0.7 log 10 copies/ml) in heavily treated patients harboring viruses resistant to most other NRTIs. The usefulness of tenofovir in salvage therapy should not necessarily preclude a possible role in initial therapy.
NNRTI RESISTANCE MUTATIONS
The NNRTIs bind to a hydrophobic pocket in the RT enzyme close to, but not contiguous with, the active site. These compounds inhibit HIV-1 replication allosterically by displacing the catalytic aspartate residues relative to the polymerase binding site (100, 198, 365) . The mutations responsible for NNRTI resistance are in the hydrophobic pocket which bind the inhibitors (Fig. 3) . A single mutation in this pocket may result in high-level resistance to one or more NNRTIs. Resistance usually emerges rapidly when NNRTIs are administered as monotherapy or in the presence of incomplete virus suppression, suggesting that resistance may be caused by the selection of a pre-existing population of mutant viruses within an individual (57, 141, 170, 400) . Like many of the PI and NRTI resistance mutations, some of the NNRTI resistance mutations may also compromise virus replication. Two mechanisms of impaired replication have been proposed: changes in the conformation of the dNTP binding pocket (194, 389) and changes in RNase H activity (4, 112) .
NNRTIs
There are three FDA-approved NNRTIs: nevirapine, delavirdine, and efavirenz. The hydrophobic binding pocket to which the NNRTIs bind is less well conserved than the dNTP binding site. Indeed, HIV-1 group O and HIV-2 (80, 151, 349, 415) are intrinsically resistant to most NNRTIs. The FDA-approved NNRTIs are highly active against group M HIV-1 isolates and the dynamic susceptibility range for each of the NNRTIs is greater than 100-fold. Wild-type HIV-1 group M isolates tend to have greater interisolate variability in their susceptibility to NNRTIs than to NRTIs and PIs (33) . However, preliminary data suggest that the moderate (Ͻ10-fold) decreases in NNRTI susceptibility that have been reported in the absence of previous NNRTI therapy or known NNRTI resistance mutations do not interfere with the virologic response to an NNRTI-containing highly active antiretroviral therapy (HAART) regimen ( 
NNRTI Mutations between Codons 98 and 108
K103N occurs more commonly than any other mutation in patients receiving NNRTIs (11, 57, 69, 78, 129) and causes 20-to 50-fold resistance to each of the available NNRTIs (11a, 78, 290, 418) . Although this degree of resistance is less than the highest levels of resistance observed with these drugs, K103N by itself appears sufficient to cause virologic failure with each of the NNRTIs (44, 78, 175, 355) . It has been proposed that K103N may have minimal effects on viral fitness and that this mutation can result in a virus that is both resistant and highly fit (69) . Structural studies of HIV-1 RT with K103N in both unliganded and bound to an NNRTI have shown that the structure is only minimally changed in that in the unliganded form it forms a network of hydrogen bonds that are not present in the wild-type enzyme (157) . These changes are likely to stabilize the closed pocket form of the enzyme and interfere with the ability of inhibitors to bind to the enzyme. A different mutation at position 103, K103R, occurs in 2 to 3% of patients not receiving NNRTIs and has not been reported to cause NNRTI resistance (177).
V106A causes Ͼ30-fold resistance to nevirapine, intermediate resistance to delavirdine, and low-level resistance to efavirenz (18, 38, 95, 108, 220, 284, 290, 418) . L100I causes intermediate resistance to efavirenz and delavirdine and low-level resistance to nevirapine (37, 38, 108, 290, 403, 418) . L100I usually occurs with K103N in patients receiving efavirenz and significantly increases efavirenz resistance in these isolates (11) . A98G, K101E, and V108I each cause low-level resistance to each of the NNRTIs (11a, 37, 290, 418) .
NNRTI Mutations between Codons 179 and 190
Y181C/I causes Ͼ30-fold resistance to nevirapine and delavirdine and 2 to 3-fold resistance to efavirenz (37, 38, 290, 418) . Nonetheless, nevirapine-treated patients with isolates containing Y181C generally have only transient virologic responses to efavirenz-containing salvage regimens (355, 398a) . It is not known whether virologic failure in this setting is due to lowlevel Y181C-mediated efavirenz resistance or to the presence of a subpopulation of viruses containing K103N that predominate upon exposure to efavirenz. Y188C/L/H causes high-level resistance to nevirapine and efavirenz and intermediate resistance to delavirdine (38, 108, 290, 418) . G190A/S causes high-level resistance to nevirapine and efavirenz but do not cause in vitro resistance to delavirdine (11a, 108, 290) . There are no clinical data, however, on the usefulness of delavirdine in patients harboring isolates with these mutations. V179D causes low-level (about twofold) resistance to each of the NNRTIs (38, 195, 403, 418) . 260 SHAFER CLIN. MICROBIOL. REV.
NNRTI Mutations between Codons 225 and 236
P225H causes low-level resistance to efavirenz and possibly nevirapine. By itself, P225H causes delavirdine hypersusceptibility. However, it usually occurs with K103N in patients receiving efavirenz (11, 11a, 284) . M230L is a recently identified uncommon mutation that causes about 20-fold resistance to efavirenz, 40-fold resistance to nevirapine, and 60-fold resistance to delavirdine (Huang, W . P236L is an uncommon mutation that causes highlevel resistance to delavirdine and hypersusceptibility to nevirapine (78, 91, 160). P236L causes slowing of both DNA 3Ј-end-and RNA 5Ј-end-directed RNase H cleavage possibly explaining the markedly decreased replication of isolates with this mutation (112) . F227L and L234I cause resistance to two experimental NNRTI but their effect on current NNRTIs is not known (18, 108) .
Other NNRTI Resistance Mutations
Mutations at codon 138 (e.g., E138K) have been shown to confer resistance to an experimental group of NNRTIs, called the TSAO inhibitors (17), but do not cause resistance to the currently approved NNRTIs (283) . This mutation exerts its effect via the p51 subunit of HIV-1 RT, which lies close to the NNRTI binding pocket (17) . Mutations at position 135 and 283 have been shown to cause low-level resistance to NNRTIs, particularly when present in combination (33) . Y318F is a mutation in the NNRTI-binding pocket which causes high-level resistance (about 40-fold) to delavirdine and low-level resistance (Ͻ3-fold) resistance to nevirapine and efavirenz (183). However, this mutation rarely occurs in the absence of other major NNRTI resistance mutations.
NNRTI Mutation Interactions
Mutational interactions within the NNRTI class (e.g., hypersusceptibility caused by P225H and P236L) have not yet been shown to be clinically significant in that there has been no demonstrated benefit of using NNRTIs either in combination or in sequence. Mutational interactions between NNRTI resistance mutations and NRTI-resistance mutations, however, will probably prove to be clinically relevant. It has been known for several years that Y181C and L100I hypersensitize HIV-1 to zidovudine (215, 216), and recently it has been shown that some NRTI-resistance mutations appear to hypersensitize HIV-1 to certain NNRTIs (352; Haubrich, R., J. Whitcomb, P. 
HIV-1 FUSION INHIBITORS
The HIV-1 envelope glycoprotein consists of two noncovalently associated subunits, a surface glycoprotein (gp120) FIG. 3 . Structural model of HIV-1 RT labeled with NNRTI resistance mutations. The polypeptide backbone of the complete p66 subunit (positions 1 to 560) and DNA primer and template strands are shown. This drawing is based on the structure published by Kohlstaedt et al. (199) in which the RT is cocrystallized with nevirapine, which is displayed in space-fill mode. The positions associated with NNRTI resistance are shown surrounding the hydrophobic pocket to which nevirapine and other NNRTIs bind.
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and a transmembrane glycoprotein (gp41). Portions of gp120 bind to both the CD4 receptor and to one of the chemokine receptors on target cells. After gp120-CD4-coreceptor binding, the gp41 subunit undergoes a conformational change that promotes fusion of viral and cellular membranes, resulting in entry of the viral core into the cell. This conformational change results in a transient species, termed the prehairpin intermediate in which gp41 exists simultaneously as a membrane protein in both the viral and cellular membranes (94) . Recent crystallographic studies of gp41 fragments show that two heptad repeat domains form a helical bundle containing trimers of each domain (45) . The first successful inhibitors of viral entry were synthetic peptides corresponding to predicted alpha helical regions of the HIV-1 gp41 sequences. One of these peptides, T-20 (pentafuside; Trimeris, Durham, N.C.), corresponds to residues 127 to 162 of the outer layer of gp41. When this peptide was administered intravenously over a twoweek period the median plasma HIV-1 RNA levels of subjects receiving the higher dose levels (100 mg twice daily) declined 100-fold (192).
The extraviral portion of gp41 is the most conserved region in the HIV-1 envelope glycoprotein, which otherwise displays considerable genetic diversity. Yet HIV-1 isolates resistant to T-20 have been derived by culturing HIV-1 in the presence of increasing concentrations of the peptide. Sequence analysis of the resistant isolates demonstrated that a contiguous 3-aminoacid sequence (codons 36 to 38) within the amino-terminal heptad repeat motif of gp41 is associated with resistance (306). T-1249 is another injectable fusion inhibitor developed by Trimeris that has a longer half-life and retains activity against T-20-resistant isolates. Additional fusion inhibitors in development include other peptides, antibodies, and small molecules that bind to either gp41 or the chemokine receptors CCR5 and CXCR4.
TECHNICAL ASPECTS OF HIV-1 GENOTYPIC TESTING IN CLINICAL SETTINGS
The following subsections review the source of virus used for sequencing in clinical settings, the method of preparing nucleic acid material for sequencing, methods of sequencing, methods of sequence quality control, and the approach to analyzing HIV-1 isolates belonging to non-B subtypes. More detailed reviews of some of these issues have been covered in other recent reviews on the technical aspects of HIV-1 genotypic testing (75, 128, 341, 392).
Source of Virus and Initial Sample Processing
Plasma is the main source of virus used for testing HIV-1 drug resistance in clinical settings. Because the half-life in of HIV-1 in plasma is approximately 6 h, only actively replicating virus can be isolated from this source; thus the sequence of plasma virus represents the quasispecies most recently selected for by antiretroviral drug therapy (287) . Plasma is easier to process and store than peripheral blood mononuclear cells and the evolution of HIV-1 drug resistance in peripheral blood mononuclear cell virus lags behind that in plasma (197, 203, 356, 361, 400) . Because HIV-1 genotypic testing requires the extraction, reverse transcription, and PCR amplification of a larger segment of the HIV-1 genome (Ͼ1 kb) than used for assays designed quantitative assays (about 100 bp) the sensitivity of most genotypic assays is generally reduced compared with quantitative assays with a lower limit of detection of between 100 and 1,000 RNA copies/ml, depending on the assay.
Population-Based versus Clonal Sequencing
Clonal sequencing is performed in research settings to answer questions about the evolution of HIV-1 drug resistance. Direct PCR or population-based sequencing is done in clinical settings because it is quicker and more affordable than sequencing multiple clones. For both population-based and clonal sequencing, the ability to detect minor variants is related to the proportion of the minor variants within the whole virus population. In direct PCR sequencing, a nucleotide mixture can be detected when the least common nucleotide is present in at least 20% of the total virus population. (62, 125, 225, 325, 340) .
Dideoxynucleotide Sequencing
Dideoxynucleotide sequencing is the most commonly used method for HIV-1 sequencing. One commercial HIV-1 RT and protease genotyping kit has been approved by the FDA for use in clinical settings (47a, 380a); a second kit is under consideration for FDA approval (61a, 267a). These kits have stronger quality control and validation profiles than home brew methods which will make them preferable in clinical laboratories. However, these kits are more expensive and may not provide the versatility of current home brew methods. The assays in these kits differ technically but are similar in overall complexity. In one recent comparison they had similar performance (96) .
Several studies indicate that dideoxynucleotide sequencing is highly reproducible in experienced laboratories. In one study, 13 research laboratories were shipped cell pellets from cultured HIV-1 isolates (76). The sequence concordance among laboratories was 99.7% at all nucleotide positions and 97% at positions associated with zidovudine resistance. Sequencing cultured cell pellets is simpler than sequencing plasma because RNA extraction and reverse transcription are not necessary and because cultured virus is more homogeneous than uncultured virus (73, 210). Nonetheless, the high interlaboratory concordance in this study attests to the intrinsic reliability of the dideoxy method for HIV-1 analysis.
Two large multicenter comparisons of sequence results obtained from samples containing mixtures of plasmid clones (ENVA-1) and spiked plasma samples (ENVA-2) have also been performed (325, 325a) . These studies found that the ability of the participating laboratories to detect mutations was directly proportional to the percent of mutant plasmid clones within each mixture. Only a minority of laboratories detected mutations in mixtures in which the mutant clones made up less than 25% of the total.
Two clinical laboratories also assessed the reproducibility of HIV-1 RT and protease sequencing using plasma aliquots obtained from 46 heavily treated HIV-1 infected individuals (333) . Although both laboratories used sequencing reagents 262 SHAFER CLIN. MICROBIOL. REV.
from Applied Biosystems (Foster City, Calif.), each used a different in-house protocol for plasma HIV-1 RNA extraction, reverse transcription, PCR, and sequencing. Overall sequence concordance between the two laboratories was 99.0%. Approximately 90% of the discordances were partial, defined as one laboratory detecting a mixture while the second laboratory detected only one of the mixture's components. Discordance was significantly more likely to occur in plasma samples with lower plasma HIV-1 RNA levels. Nucleotide mixtures were detected at approximately 1% of the nucleotide positions, and, in every case in which one laboratory detected a mixture, the second laboratory detected either the same mixture or one of the mixture's components. The high concordance in detecting mixtures and the fact that most discordance between the two laboratories was partial suggest that most discordances were due to variation in sampling the HIV-1 quasispecies rather than to technical errors.
Hybridization Methods
Sequencing by hybridization can determine the complete sequence of an unknown DNA molecule or detect specific mutations. The Affymetrix GeneChip is designed to determine the complete sequence of HIV-1 protease and the first 1,200 nucleotides of HIV-1 RT. The INNO-LiPA HIV-1 line probe assays (Innogenetics, Ghent, Belgium) are point mutation assays designed to detect specific HIV-1 protease and RT mutations.
The GeneChip is divided into several thousand segments each containing millions of similar probes designed to interrogate every nucleotide position in a test DNA or RNA molecule. Every nucleotide in the test molecule requires at least four sets of oligonucleotide probes to determine whether that nucleotide is an A, C, G, or U. It is essential that the probe hybridizes perfectly to the nucleotides on either side of the position being interrogated. The design or tiling of Affymetrix gene chips therefore requires prior knowledge of the most commonly expected polymorphisms in a gene. Because of this requirement, this method of sequencing is also referred to as resequencing.
Because of its genetic variability, sequencing HIV-1 by hybridization is challenging. Several studies have compared the performance of the GeneChip to dideoxynucleotide cycle sequencing and most have found that dideoxynucleotide sequencing is more reliable at detecting HIV-1 RT and protease mutations (125, 130, 386, 402) . DNA chips are also not capable of detecting insertions or deletions in viral sequences and are unreliable at sequencing viral subtypes other than subtype B-the subtype on which the chip tiling has been based. In addition, genomic regions containing clusters of adjacent mutations can interfere with probe hybridization and result in frank errors (130, 386) . Improved microarrays for sequencing isolates belonging to subtypes A- Point mutation assays are inexpensive and have the potential to be highly sensitive for mutations present in only a small proportion of circulating viruses (328, 388) . Because they require only simple laboratory equipment, they may be useful in areas that do not have ready access to sophisticated sequencers. The INNO-LiPA assays have probes for wild-type and mutant alleles of each codon attached to a nitrocellulose strip (48, 371) . Biotin-labeled RT-PCR product from the patient sample is hybridized to the strip. An avidin-enzyme complex and the enzyme substrate produce a color change on the paper strip where the PCR product has hybridized with a probe. This assay is limited because it can only detect a subset of drug resistance mutations and has a 10% rate of uninterpretable results due to poor hybridization, which is particularly likely to occur when uncommon mutations are present at key codons (298, 328) .
Sequence Quality Control
Sequence quality control should aim at avoiding PCR contamination and sample mix-ups, obtaining high quantities of specific template DNA, and detecting as many mixtures as possible. Laboratories should use standard physical precautions to prevent sample contamination with DNA from other sources (211) and negative controls should be run with each PCR step. Alternate primers for reverse transcription and/or PCR sequencing should be used on samples that cannot be amplified despite plasma HIV-1 RNA levels Ͼ1,000 copies/ml. Heat-stable RNase H Ϫ RT enzymes can be used to increase the yield of the reverse transcription step. A uracil N-glycosylase (UNG) system can be used to minimize contamination of PCRs with products generated in previous amplifications.
Sequence analyses can detect the possibility of contamination with other samples studied during the same time period (228) . These analyses should compare each new sequence to other recently generated sequences to look for unexpectedly high levels of similarity. Phylogenetic trees can also be constructed to visually detect unexpectedly similar isolates. The HIV Sequence Database at Los Alamos National Laboratories has a tutorial to assist with sequence analysis for quality control purposes (204) .
Global HIV-1 Isolates
During its spread among humans, group M HIV-1 has evolved into multiple subtypes that differ from one another by 10 to 30% along their genomes (201, 307) . In North America and Europe, most HIV-1 isolates belong to subtype B and the available anti-HIV drugs have been developed by drug screening and susceptibility testing using subtype B isolates. However, subtype B accounts for only a small proportion of HIV-1 isolates worldwide and non-B isolates are being identified with increasing frequency, particularly in Europe.
A few studies have tested the in vitro susceptibility of nonsubtype B HIV-1 isolates to antiretroviral drugs. Although group O isolates often demonstrate intrinsic resistance to the NNRTIs (80, 299), most studies have shown that non-B group M isolates are as susceptible as subtype B isolates to each of the three anti-HIV drug classes (276, 331, 332, 374) . There is no evidence for novel drug resistance mutations in non-B HIV-1 isolates and most available data suggest that drug resistance mutations described in the context of subtype B iso-VOL. 15, 2002 GENOTYPIC TESTING FOR HIV-1 DRUG RESISTANCElates will exert the same phenotypic effects in all HIV-1 subtypes.
Intersubtype genetic variability may complicate HIV-1 genotyping because primers used for reverse transcription, PCR, and sequencing may have a lower rate of annealing to non-B compared with subtype B templates. But the extent to which this occurs has not been studied. Both the Applied Biosystems ViroSeq HIV-1 Genotyping System have been used for the analysis of non-B isolates, but the primers used in both commercial systems are proprietary (98a, 267a) and the Visible Genetics TRUGENE HIV-1 Genotyping System (213).
GENOTYPIC INTERPRETATION General Principles
HIV-1 drug resistance is rarely an all-or-none phenomenon. Clinicians treating infected patients usually need the answers to the following two questions: (i) Does the genotype suggest that the patient will respond to a drug in a manner comparable to a patient with a wild-type isolate? (ii) Does the genotype suggest that the patient will obtain any antiviral benefit from the drug? The second question distinguishes antiviral susceptibility testing from anti-bacterial susceptibility testing. In the case of bacteria, it is usually possible to avoid using any drug with reduced susceptibility against a pathogen. This is usually not possible in the case of HIV, however, because of the extent of cross-resistance within each class of HIV drugs. To answer both these questions it is necessary to grade the extent of inferred resistance relative to the wild type and to the most resistant isolates (e.g., low-level, intermediate, and high-level).
Genotypic results bear little resemblance to those of a typical antimicrobial susceptibility assay. Rather than receiving a result such as susceptible or resistant for each of the available HIV drugs, the ordering clinician receives a list of mutations present in the virus isolate. The difficulty in understanding the results of these genotypic assays and the fact that genotypic interpretation is independent of the process of genotyping makes it an ideal application for a computerized expert system. Laboratories doing HIV-1 genotyping can provide physicians with the option of receiving a file with the sequence data (string of nucleotides or list of amino acid differences from consensus). Such data can then be analyzed by interpretation systems other than those used by the sequencing laboratory.
An expert system performs reasoning over representations of human knowledge. It consists of a computerized knowledge base and an inference engine. A computerized knowledge base has benefits for patients, clinicians, and researchers because it can identify gaps in what is known about drugs and drug resistance mutations and homogeneous data, such as genotypephenotype correlations, are amenable to machine learning algorithms. In contrast, diverse forms of data such as phenotypic and clinical data, are amenable to rules-based algorithms. Table 6 describes the requirements of an expert system for HIV-1 genotypic interpretation: data input, knowledge base, inference engine, and data output. Table 7 describes several of the most commonly used systems for HIV-1 genotypic interpretation. During the next one to two years, these algorithms will evolve and most likely converge through an ongoing process of interalgorithm comparison and validation using clinical data sets. This is because there is probably more concordance among clinical virologists than is currently reflected in published algorithms. It is unlikely that algorithms will remain proprietary because there is no precedent for basing important medical decisions on proprietary unpublished data. The following two sections explore two algorithms in detail: VirtualPhenotype and the HIVDB algorithm.
VirtualPhenotype
The VirtualPhenotype (Virco, Cambridge, United Kingdom, and Mechelin, Belgium) is a pattern-matching algorithm that uses a large genotypic-phenotypic correlative database to infer phenotypic properties based on sequence data (Verbiest, W., M. Peeters, K. . The analysis includes a tabulation of the number of matches in the database for each drug, and the distribution of phenotypes (fold increase in IC 50 ) for the matching samples. The mean IC 50 of the matching samples is interpreted using a biologically defined, drug-specific cutoff value, providing a quantitative prediction of drug resistance. Although the VirtualPhenotype has been described in several abstracts, there is no publication that describes the workings of this approach in its entirety. Specifically, it is not known which mutations are used to match a new sequence to those sequences that are already in the database.
The VirtualPhenotype has been shown to have a high correlation with results from Virco's recombinant phenotypic assay (Graham, N., M. Peeters, W. Verbeist, R. Harrigan, and B. Larder, abstract 524, 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., 2001). It has also been compared to rule-based algorithms using the data set from a completed clinical trial (126) . Further studies examining the predictive value of the VirtualPhenotype using data from other clinical trials is planned.
HIV RT and Protease Sequence Database
The HIV RT and Protease Sequence Database at Stanford University is an online database (http://hivdb.stanford.edu) that links sequence data to the HIV drug treatments of the patients from whom the sequenced isolates were obtained and to drug susceptibility results. The database also contains two sequence analysis programs. HIV-SEQ accepts user-submitted RT and protease sequences, compares them to a reference sequence, and uses the differences as query parameters for interrogating the sequence database (336) . This allows users to detect unusual sequence results immediately so that the person doing the sequencing can check the primary sequence output while it is still on the desktop. In addition, unexpected associations between sequences or isolates can be discovered by immediately retrieving data on isolates sharing one or more mutations with the sequence.
The second program, Drug Resistance Interpretation, is an expert system that accepts user-submitted protease and RT sequences and returns inferred levels of resistance to the 16 FDA-approved anti-HIV drugs. Each drug resistance mutation is assigned a drug penalty score; the total score for a drug is 
LIMITATIONS OF HIV-1 DRUG RESISTANCE TESTING
Several factors limit the utility of both genotypic and phenotypic testing. (i) There is a complex relationship between drug resistance and clinical failure, often making it difficult to discern the contribution of drug resistance to virologic failure.
(ii) The HIV-1 population within an individual consists of innumerable variants and minor variants often go undetected. (iii) Because of extensive cross-resistance within each drug class, the results of resistance testing often leave clinicians with few options for treatment.
Complex Relationship between Drug Resistance and Disease Progression
Drug resistance is not the only cause of treatment failure. Nonadherence, the use of insufficiently potent treatment regimens, and pharmacokinetic factors that decrease the levels of one or more drugs in a treatment regimen also contribute to treatment failure. In addition, the natural history of HIV-1 is highly variable and dependent on a complex set of host-virus interactions (273) . In the absence of therapy some patients progress to advanced immunodeficiency within 3 years following infection, whereas other patients remain healthy for more than 15 years. It is likely that the same host-virus interactions that so greatly influence disease progression in the absence of drug therapy also influence the risk of virologic failure in patients receiving anti-HIV therapy.
Two recent observations underscore the complexity of the relationship between drug resistance and disease progression. The first is that patients developing virologic failure on their first treatment regimen are usually found to have HIV-1 isolates with resistance to only one of the drugs in the regimen (81, 110, 142, 236, 267, 268) . The drugs to which resistance most commonly develops in this situation are lamivudine and the NNRTIs; resistance to PIs and NRTIs is less common in patients with initial virologic failure. The fact that virus becomes detectable and replication ensues despite the fact that the replicating virus remains sensitive to at least two drugs suggests that factors in addition to drug resistance are contributing to virologic failure. Possibly the remaining drugs in the regimen are not potent enough to fully suppress virus even though they remain active. Alternatively, one of the presumably "effective" drugs in the regimen may be present at insufficient levels because of nonadherence or pharmacokinetic factors.
The second observation is that virologic failure in patients receiving HAART is not always followed by immunologic and clinical deterioration (20, 71, 229, 295) . This may be because the immunologic benefits of virus suppression persist beyond the period of virus suppression or because multidrug-resistant viruses may be less virulent, particularly when they first emerge and are associated with fewer compensatory mutations (83, 292). Several lines of evidence suggest that drug-resistant viruses are less fit than drug-susceptible viruses. First, in vitro experiments have consistently shown that isolates containing protease and/or RT drug resistance mutations replicate less well in cell culture and that purified enzymes with these mutations usually have less activity than wild-type enzymes (reviewed in reference 271). There are conflicting data, however, on whether multidrug-resistant variants are less cytopathic in specific types of cells (e.g., thymus) (231, 286, 370) . Second, drug resistance mutations are often replaced in vivo by wild-type variants within weeks to months after removal of selective drug pressure (83, 84, 116, 117, 395) . The rate at which this occurs depends on the extent to which archived wild type viruses exist within an individual patient. If there are no archived wild-type viruses, a significant interlocking of primary and compensatory mutations may limit reversion to wild type (21) .
Finally, one clinical trial in patients with detectable viremia and mulitdrug-resistant virus showed that in those patients randomized to discontinuing HIV therapy, RNA decreased by 0.84 logs and CD4 cell counts decreased by 128 cells/l. This study suggests that the decreases in the fitness of drug-resistant viruses seen in vitro are clinically significant and that continuing drug therapy in the face of resistance may have utility in patients with few other therapeutic options. However, the possibility that many of the isolates in this study retained some degree of susceptibility to one or more drugs in treatment regimens that were used, cannot be excluded.
Quasispecies Nature of HIV-1
The inability to reliably detect minor drug-resistant HIV-1 variants is a recognized limitation of HIV-1 drug susceptibility testing using either genotypic or phenotypic methods. This is particularly troublesome in patients with complicated treatment histories or in patients who have discontinued one or more antiretroviral drugs (84, 395). To maximize the likelihood that a sequence will identify mutations present within the virus population of a patient, it is important to obtain plasma samples for resistance testing before stopping or changing antiretroviral drugs and to consider a patient's treatment history when interpreting the results of resistance testing.
In some patients, the treatment history can be used to infer the presence of archived drug resistance mutations. For example, if a patient previously received lamivudine as part of an incompletely suppressive treatment regimen, it is likely that M184V exists within the virus population of that patient even if it is not detected at the time of genotyping. The same principle would apply to patients who received NNRTIs as part of an incompletely suppressive treatment regimen; however, in this situation, it would not be possible to know specifically which NNRTI mutations are likely to be archived. In contrast, patients receiving lamivudine and NNRTIs as part of com-VOL. 15, 2002 GENOTYPIC TESTING FOR HIV-1 DRUG RESISTANCE 265 pletely suppressive treatment regimens are not expected to harbor variants resistant to these drugs. If a patient once harbored drug-resistant variants, these variants may persist at low levels in latently infected cells even if a subsequent treatment regimen brings about complete virus suppression (103, 146, 163, 245, 411) . In patients in whom previous resistance tests have documented extensive drug resistance, the clinical usefulness of repeated resistance testing is likely to be minimal, because many resistant variants selected by previous treatment regimens will go undetected in future tests, yet are likely to emerge during attempts at salvage therapy.
Cross-Resistance
Most mutations arising during drug therapy contribute resistance to multiple drugs within the same drug class. This is particularly problematic considering that there are just three drug classes and that combinations of drugs from at least two classes are usually required to achieve durable HIV-1 suppression. Genotypic assays frequently do not identify enough fully active non-cross-resistant drugs to completely block HIV-1 replication and many patients changing regimens because of virologic failure will have to use a regimen containing drugs that are partially compromised at the start of therapy. Although cross-resistance is not a direct limitation of genotypic or phenotypic testing, it limits the utility of resistance testing particularly in heavily treated patients. Nonetheless, resistance assays have a role even in heavily treated patients because they provide prognostic data and help avoid unnecessary drugs. Rather than including fully active drugs, salvage therapy in heavily treated patients will have to include drug combinations that exploit antagonistic mutational interactions or generate high in vivo drug levels. 
